These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11889242)

  • 21. Cerebral degeneration predicts survival in amyotrophic lateral sclerosis.
    Kalra S; Vitale A; Cashman NR; Genge A; Arnold DL
    J Neurol Neurosurg Psychiatry; 2006 Nov; 77(11):1253-5. PubMed ID: 16835288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis.
    Cervo A; Cocozza S; Saccà F; Giorgio SMDA; Morra VB; Tedeschi E; Marsili A; Vacca G; Palma V; Brunetti A; Quarantelli M
    Eur J Radiol; 2015 Jan; 84(1):151-157. PubMed ID: 25466774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis.
    Atassi N; Xu M; Triantafyllou C; Keil B; Lawson R; Cernasov P; Ratti E; Long CJ; Paganoni S; Murphy A; Salibi N; Seethamraju R; Rosen B; Ratai EM
    PLoS One; 2017; 12(5):e0177680. PubMed ID: 28498852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ratio of N-acetyl aspartate to glutamate correlates with disease duration of amyotrophic lateral sclerosis.
    Sako W; Abe T; Izumi Y; Harada M; Kaji R
    J Clin Neurosci; 2016 May; 27():110-3. PubMed ID: 26765768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motor cortex metabolite alterations in amyotrophic lateral sclerosis assessed in vivo using edited and non-edited magnetic resonance spectroscopy.
    Weerasekera A; Peeters R; Sima D; Dresselaers T; Sunaert S; De Vocht J; Claeys K; Van Huffel S; Van Damme P; Himmelreich U
    Brain Res; 2019 Sep; 1718():22-31. PubMed ID: 31002818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALS surrogate markers. MRS.
    Kalra S; Arnold DL
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():111-4. PubMed ID: 15512889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements.
    Block W; Karitzky J; Träber F; Pohl C; Keller E; Mundegar RR; Lamerichs R; Rink H; Ries F; Schild HH; Jerusalem F
    Arch Neurol; 1998 Jul; 55(7):931-6. PubMed ID: 9678310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients.
    Pohl C; Block W; Träber F; Schmidt S; Pels H; Grothe C; Schild HH; Klockgether T
    J Neurol Sci; 2001 Sep; 190(1-2):21-7. PubMed ID: 11574102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy.
    Kalra S; Hanstock CC; Martin WR; Allen PS; Johnston WS
    Arch Neurol; 2006 Aug; 63(8):1144-8. PubMed ID: 16908742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton magnetic resonance spectroscopy in patients with early stages of amyotrophic lateral sclerosis.
    Sivák S; Bittšanský M; Kurča E; Turčanová-Koprušáková M; Grofik M; Nosál' V; Poláček H; Dobrota D
    Neuroradiology; 2010 Dec; 52(12):1079-85. PubMed ID: 20369234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
    Ciurleo R; Bonanno L; Di Lorenzo G; Bramanti P; Marino S
    Neurosci Lett; 2015 Jul; 599():55-60. PubMed ID: 26007705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy.
    Kalra S; Cashman NR; Genge A; Arnold DL
    Neuroreport; 1998 Jun; 9(8):1757-61. PubMed ID: 9665596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy.
    Kalra S; Cashman NR; Caramanos Z; Genge A; Arnold DL
    AJNR Am J Neuroradiol; 2003 Mar; 24(3):476-80. PubMed ID: 12637300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging.
    Bertolino A; Nawroz S; Mattay VS; Barnett AS; Duyn JH; Moonen CT; Frank JA; Tedeschi G; Weinberger DR
    Am J Psychiatry; 1996 Dec; 153(12):1554-63. PubMed ID: 8942451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
    Raizer JJ; Koutcher JA; Abrey LE; Panageas KS; DeAngelis LM; Lis E; Xu S; Zakian KL
    J Neurooncol; 2005 Jan; 71(2):173-80. PubMed ID: 15690135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurochemical correlates of functional decline in amyotrophic lateral sclerosis.
    Cheong I; Deelchand DK; Eberly LE; Marjańska M; Manousakis G; Guliani G; Walk D; Öz G
    J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):294-301. PubMed ID: 30467209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic resonance imaging and magnetic resonance spectroscopy in a patient with amyotrophic lateral sclerosis and frontotemporal dementia.
    Sarac H; Zagar M; Vranjes D; Henigsberg N; Bilić E; Pavlisa G
    Coll Antropol; 2008 Jan; 32 Suppl 1():205-10. PubMed ID: 18405084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain.
    Chan S; Shungu DC; Douglas-Akinwande A; Lange DJ; Rowland LP
    Radiology; 1999 Sep; 212(3):763-9. PubMed ID: 10478245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-brain proton MR spectroscopic imaging in Parkinson's disease.
    Levin BE; Katzen HL; Maudsley A; Post J; Myerson C; Govind V; Nahab F; Scanlon B; Mittel A
    J Neuroimaging; 2014; 24(1):39-44. PubMed ID: 23228009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS.
    Mitsumoto H; Ulug AM; Pullman SL; Gooch CL; Chan S; Tang MX; Mao X; Hays AP; Floyd AG; Battista V; Montes J; Hayes S; Dashnaw S; Kaufmann P; Gordon PH; Hirsch J; Levin B; Rowland LP; Shungu DC
    Neurology; 2007 Apr; 68(17):1402-10. PubMed ID: 17452585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.